Knowledge

SemBioSys Genetics

Source đź“ť

187:
and prescription topical dermatology products. Botaneco produced, marketed, and sold its products under the brand name Hydresia. In October 2009, Botaneco merged with Quebec City-based Advitech, a health sciences and technology company.
320:
Quote: "This partnership has not resulted in any financial benefit to SemBioSys to date and, as a result, the company has not transferred any intellectual property to the newly formed joint venture as of this
244: 317: 207:, China. The new company was structured as a Sino-Foreign Equity Joint Venture and seeks to develop and commercialize a variety of products including pharmaceutical, functional foods, and 263: 278: 164:
The company's strategy was to partner with other companies to enable the commercialization of products. Its lead pharmaceutical products under development were
353: 241: 183:
In 2007, SemBioSys formed a subsidiary, Botaneco Specialty Ingredients Inc., dedicated to the commercialization of SemBioSys’ products for cosmetic,
211:
for China and the world. However SemBioSys did not transfer any intellectual property to the joint venture and Tasly terminated the agreement.
138: 302: 260: 203:(TCMs). Upon government approval, a new company called Tasly-SemBioSys Bio-Pharmaceuticals Co., Ltd. was incorporated in 200: 338: 220: 192: 154: 134: 333: 242:
Press release May 15, 2012: SemBioSys Announces First Quarter Results and Provides Update on Activities
137:
spin-off (1994), SemBioSys became a publicly traded firm. Investors had included Bay City Capital, the
199:(China) and its wholly owned subsidiary Tasly U.S. Tasly is of China's top five largest producers of 150: 146: 126: 106: 165: 142: 47: 306: 267: 248: 158: 122: 208: 130: 28: 172:. In a phase I/II clinical trial, SemBioSys demonstrated that its safflower produced 347: 299: 184: 169: 118: 99: 96: 103: 110: 204: 196: 177: 173: 53: 191:
In October 2011, SemBioSys signed a collaboration agreement with
114: 84: 237: 235: 161:. In May 2012, SemBioSys terminated its operations. 80: 70: 60: 42: 34: 24: 261:Plant-derived insulin passes first human study 8: 19: 318:SenBioSys News Release 2012-04-04 07:31 ET 18: 231: 157:, Ventures West Capital Ltd., and Dr. 7: 180:, a commercially available insulin. 139:Business Development Bank of Canada 259:The Pharma Letter. 30 March 2009. 102:company. It utilized its patented 14: 354:Biotechnology companies of Canada 149:), Royal Bank Ventures Inc. (now 176:(SBS-1000) is bioequivalent to 66:James Szarko, President and CEO 279:Bloomberg BusinessWeek Profile 145:(a Canadian subsidiary of The 1: 201:traditional Chinese medicines 109:platform to develop and make 16:Definct biotechnology company 370: 305:February 16, 2015, at the 221:Plant-made pharmaceuticals 247:August 15, 2012, at the 95:was a development stage 93:SemBioSys Genetics Inc. 20:SemBioSys Genetics Inc. 300:Tasly Export Statement 266:June 27, 2010, at the 193:Tasly Pharmaceuticals 155:University of Calgary 135:University of Calgary 151:RBC Capital Partners 147:Dow Chemical Company 72:Number of employees 21: 166:biosimilar insulin 334:SemBioSys Website 90: 89: 85:www.sembiosys.com 361: 322: 315: 309: 297: 291: 287: 281: 276: 270: 257: 251: 239: 143:Dow AgroSciences 76:Approximately 20 48:Calgary, Alberta 22: 369: 368: 364: 363: 362: 360: 359: 358: 344: 343: 330: 325: 316: 312: 307:Wayback Machine 298: 294: 288: 284: 277: 273: 268:Wayback Machine 258: 254: 249:Wayback Machine 240: 233: 229: 217: 159:Maurice Moloney 133:industries. A 123:functional food 73: 63: 56: 50: 17: 12: 11: 5: 367: 365: 357: 356: 346: 345: 342: 341: 336: 329: 328:External links 326: 324: 323: 310: 292: 282: 271: 252: 230: 228: 225: 224: 223: 216: 213: 209:nutraceuticals 170:Apo AI(Milano) 131:pharmaceutical 88: 87: 82: 78: 77: 74: 71: 68: 67: 64: 61: 58: 57: 52: 46: 44: 40: 39: 36: 32: 31: 26: 15: 13: 10: 9: 6: 4: 3: 2: 366: 355: 352: 351: 349: 340: 339:Tasly Website 337: 335: 332: 331: 327: 319: 314: 311: 308: 304: 301: 296: 293: 289: 286: 283: 280: 275: 272: 269: 265: 262: 256: 253: 250: 246: 243: 238: 236: 232: 226: 222: 219: 218: 214: 212: 210: 206: 202: 198: 194: 189: 186: 185:personal care 181: 179: 175: 171: 167: 162: 160: 156: 152: 148: 144: 140: 136: 132: 128: 124: 120: 119:nutraceutical 116: 112: 108: 105: 101: 100:biotechnology 98: 94: 86: 83: 79: 75: 69: 65: 59: 55: 49: 45: 41: 38:Biotechnology 37: 33: 30: 27: 23: 313: 295: 285: 274: 255: 190: 182: 163: 97:agricultural 92: 91: 43:Headquarters 25:Company type 227:References 62:Key people 104:safflower 348:Category 303:Archived 264:Archived 245:Archived 215:See also 127:beverage 117:for the 111:proteins 107:pharming 35:Industry 205:Tianjin 197:Tianjin 178:humulin 174:insulin 153:), the 81:Website 321:date." 129:, and 54:Canada 29:Public 168:and 125:and 115:oils 113:and 195:of 350:: 234:^ 141:, 121:, 51:, 290:]

Index

Public
Calgary, Alberta
Canada
www.sembiosys.com
agricultural
biotechnology
safflower
pharming
proteins
oils
nutraceutical
functional food
beverage
pharmaceutical
University of Calgary
Business Development Bank of Canada
Dow AgroSciences
Dow Chemical Company
RBC Capital Partners
University of Calgary
Maurice Moloney
biosimilar insulin
Apo AI(Milano)
insulin
humulin
personal care
Tasly Pharmaceuticals
Tianjin
traditional Chinese medicines
Tianjin

Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.

↑